Background
==========

The frequency of anti-Ro/SSA in SSc varies from 3% to 11% with immunoprecipitation assays and from 12% to 37% with ELISA. Significant associations were reported between anti-Ro/SSA and Sjögren\'s syndrome, pulmonary involvement and myositis in patients with SSc.

Objective
=========

To evaluate the frequency the association of anti-Ro/SSA antibodies and their fine specificity with clinical and immunological features in SSc.

Patients and methods
====================

We studied 193 patients with SSc (58 diffuse, 129 limited and 6 overlap syndromes) attending our outpatient clinic. Antibodies to ENA were determined by counter-immunoelectrophoresis (CIE) using rabbit thymus (Peel-Freeze) and human spleen extract as substrates. ELISA assay with recombinant 52 and 60 kD Ro proteins (Pharmacia) was performed on 107 sera, cut-off values were determined testing 75 sera from routine: 50 ANA negative and 25 ANA positive-ENA negative.

Results
=======

Anti-Ro was detected by CIE in 12/193 patients (6%) and by ELISA in 14/107 (13%). As a whole, CIE and/or ELISA detected the presence of anti-Ro in 20 patients (Ro+). It was significantly associated with photosensitivity (*P* = 0.02), xerophtalmia (*P* = 0.05), raised ESR (*P* = 0.02), hyperγ globulinemia (*P* = 0.002), anti-La (*P* = 0.004) and antinucleolar antibodies (*P* = 0.02). Anti-Scl70 antibodies tended to be specifically associated with anti-Ro60 as compared with anti-Ro52 antibodies (*P* = 0.06). Anti-Ro+ patients had higher incidence of interstitial lung disease and slight reduction of DLCO at the moment of first evaluation, as compared with patients Ro-- (*P* = 0.06), particularly with the subset anticentromere positive (*P* = 0.001). However, decrease of DLCO during follow-up was more frequent in patients Ro-- (*P* \< 0.001). This observation might be partially related to a longer steroid treatment received by patients Ro+ (*P* \< 0.03).

Conclusion
==========

Antibodies to Ro/SSA are not infrequently detected in SSc. They are associated with a subset of disease characterized by clinical and serological features commonly associated with anti-Ro/SSA independently from the underlying disease. Anti-Ro+ SSc patients tended to have an earlier lung involvement apparently less evolving as compared to anti-Ro-- patients.
